文献速递消化系统肿瘤

免疫治疗对比最佳支持治疗用于Child-Pugh B级肝功能异常的肝细胞癌患者

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项回顾性、多中心、国际临床病例系列研究比较了基于免疫检查点抑制剂的方案与最佳支持治疗在Child-Pugh B级不可切除肝细胞癌患者中的总生存。经倾向评分加权后,免疫治疗组中位总生存为7.50个月,最佳支持治疗组为4.04个月,风险比为0.59。

要点

  • 在Child-Pugh B级不可切除肝细胞癌中,基于ICI的治疗与BSC相比,经IPTW后中位OS为7.50个月对4.04个月。
  • 多变量分析显示ICI暴露与约50%的死亡风险降低相关,风险比为0.55。
  • 门静脉癌栓、ECOG体能状态评分大于1、甲胎蛋白≥400 ng/mL与死亡风险增加相关。

核心结论

  • 该病例系列的结果提供了比较证据,表明在Child-Pugh B级肝功能异常的不可切除肝细胞癌患者中,基于ICI的治疗与BSC相比与生存改善相关。

研究设计与样本

  • 回顾性、多中心、国际临床病例系列,纳入2017年9月至2022年12月接受一线ICI方案治疗的Child-Pugh B级不可切除肝细胞癌患者,并与一个接受BSC的Child-Pugh B级队列比较。
  • 患者在欧洲、美国和亚洲的三级医疗中心接受常规临床实践治疗。
  • 应用纳入标准后,ICI组187例,BSC组156例。
  • 倾向评分计算的变量包括年龄、甲胎蛋白水平、Child-Pugh评分、肝外转移、门静脉癌栓、肝硬化、腹水和基线ECOG体能状态。

主要发现

  • ICI组中位年龄66岁(IQR,61-72),女性33例(18%);BSC组中位年龄73岁(IQR,66-81),女性41例(26%)。
  • 在IPTW人群中,ICI组中位OS为7.50个月(95% CI,5.62-11.15),BSC组为4.04个月(95% CI,3.03-5.03),风险比0.59(95% CI,0.43-0.80),P < .001。
  • 多变量分析确认ICI暴露与约50%的死亡风险降低相关(风险比0.55;95% CI,0.35-0.86;P < .001)。
  • 门静脉癌栓、ECOG体能状态评分大于1和甲胎蛋白水平≥400 ng/mL与死亡风险增加相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated. OBJECTIVE: To evaluate the association of immune checkpoint inhibitor (ICI)-based therapies vs BSC with overall survival (OS) of patients with uHCC and CP-B liver dysfunction. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter, international clinical case series examined data of patients with CP-B with uHCC who were receiving first-line ICI-based regimens from September 2017 to December 2022 whose data were extracted from an international consortium and compared with a cohort of patients with CP-B receiving BSC. Patients were treated in tertiary care centers across Europe, US, and Asia in routine clinical practice. After applying the inclusion criteria, 187 and 156 patients were left in the ICI and BSC groups, respectively. The propensity score was calculated for the following variables: age, alpha-fetoprotein levels, Child-Pugh score, extrahepatic spread, portal vein tumor thrombosis, cirrhosis, ascites, and baseline Eastern Cooperative Oncology Group performance status. EXPOSURES: Patients in the ICI group received first-line systemic therapy with either atezolizumab plus bevacizumab (A+B) (n = 141) or nivolumab (n = 46). MAIN OUTCOMES AND MEASURES: OS in the inverse probability of treatment weighting (IPTW) populations was the main outcome, and it was estimated with Kaplan-Meier method; univariable Cox regression test was used to make comparisons between the 2 groups. RESULTS: The median age was 66 (IQR, 61-72) and 73 (IQR, 66-81) years in the ICI (33 women [18%]) and BSC groups (41 women [26%]), respectively. In the IPTW populations, median OS was significantly longer in the ICI group (7.50 months; 95% CI, 5.62-11.15) compared with BSC (4.04 months; 95% CI, 3.03-5.03; hazard ratio, 0.59; 95% CI, 0.43-0.80; P < .001). Multivariable analysis confirmed that ICI exposure was associated with a reduction of approximately 50% in the risk of death (hazard ratio, 0.55; 95% CI, 0.35-0.86; P < .001), and the presence of portal vein tumor thrombosis, an Eastern Cooperative Oncology Group performance score of greater than 1, and alpha-fetoprotein levels of 400 ng/mL or greater were associated with increased risk of death. CONCLUSIONS AND RELEVANCE: The results of this case series provide comparative evidence of improved survival in association with ICI treatment compared with BSC in patients with uHCC with CP-B liver dysfunction.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Fulgenzi CAM, Scheiner B, D'Alessio A, et al. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024. PMID: 39023864. doi:10.1001/jamaoncol.2024.2166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。